Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael A. Schwarzschild, M.D., Ph.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Biography
awards and honors
1985
Markey Fellowship award, HMS
1987 - 1988
Ryan Fellowship award, HMS
1994 - 1999
Clinical Investigator Development Award, NIH
1999 - 2002
George C. Cotzias Memorial Fellowship Award, APDA
2001
Fox Foundation inaugural research grant program award Awardee
2002 - 2005
Paul Beeson Faculty Scholar in Aging Research Program awardee, AFAR
2005 - 2006
Dorothy Dillon Eweson Lectureships, AFAR
2006
Partners in Excellence Award (mentoring)
2012 - 2018
Elected Chair, Executive Committee, Parkinson Study Group
2013
Member, Linked Clinical Trials Committee, Cure Parkinson's Trust
2018 - 2024
Elected Chair, Executive Committee, Parkinson Study Group
2017 - 2019
Scientific Advisory Board member, Michael J. Fox Foundation for Parkinson's Research

Overview

Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
Most Recent  |  List All
  1. R01NS110879 (SCHWARZSCHILD, MICHAEL A) Aug 1, 2019 - May 31, 2024
    NIH/NINDS
    Urate-LRRK2 interactions in Parkinson's disease
    Role: Principal Investigator
  2. R13NS111953 (SCHWARZSCHILD, MICHAEL A) Apr 1, 2019 - Mar 31, 2022
    NIH/NINDS
    2019 Parkinson Study Group Symposium and Training
    Role: Principal Investigator
  3. U01NS107009 (SCHWARZSCHILD, MICHAEL A) Jul 1, 2018 - Apr 30, 2023
    NIH/NINDS
    Tele-Health Extension for Phase 3 Parkinson's Disease Trial Cohorts
    Role: Principal Investigator
  4. U13NS103523 (SCHWARZSCHILD, MICHAEL A) Jul 1, 2017 - Jun 30, 2018
    NIH/NINDS
    2017 Parkinson Study Group Symposium and Training
    Role: Principal Investigator
  5. R13NS098746 (SCHWARZSCHILD, MICHAEL A) Aug 1, 2016 - Jul 31, 2017
    NIH/NINDS
    2016 Parkinson Study Group Symposium and Training
    Role: Principal Investigator

Featured Content
Featured Videos

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Bjornevik K, Schwarzschild MA, Ascherio A. Big health data and Parkinson's disease epidemiology: Challenges and opportunities. Parkinsonism Relat Disord. 2020 Jan 07. PMID: 31948788.
    Citations:    
  2. Alcalay RN, Kehoe C, Shorr E, Battista R, Hall A, Simuni T, Marder K, Wills AM, Naito A, Beck JC, Schwarzschild MA, Nance M. Correction: Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists. Genet Med. 2019 Nov 27. PMID: 31772350.
    Citations:    
  3. Shen Y, Li J, Schwarzschild M, Pavlova M, He S, Ascherio A, Wu S, Cui L, Gao X. Plasma urate concentrations and possible REM sleep behavior disorder. Ann Clin Transl Neurol. 2019 Dec; 6(12):2368-2376. PMID: 31714690.
    Citations:    
  4. Hughes KC, Gao X, Molsberry S, Valeri L, Schwarzschild MA, Ascherio A. Physical activity and prodromal features of Parkinson disease. Neurology. 2019 Dec 03; 93(23):e2157-e2169. PMID: 31719136.
    Citations:    
  5. Alcalay RN, Kehoe C, Shorr E, Battista R, Hall A, Simuni T, Marder K, Wills AM, Naito A, Beck JC, Schwarzschild MA, Nance M. Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists. Genet Med. 2019 Nov 04. PMID: 31680121.
    Citations:    
  6. Schwarzschild MA, Macklin EA, Bakshi R, Battacharyya S, Logan R, Espay AJ, Hung AY, Bwala G, Goetz CG, Russell DS, Goudreau JL, Parashos SA, Saint-Hilaire MH, Rudolph A, Hare JM, Curhan GC, Ascherio A. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. 2019 10 01; 93(14):e1328-e1338. PMID: 31484712.
    Citations:    
  7. Bakshi R, Macklin EA, Schwarzschild MA. Reply to "Mitochondrial DNA deletions discriminate affected from unaffected LRRK2 mutation carriers". Ann Neurol. 2019 Aug; 86(2):326-327. PMID: 31148194.
    Citations:    
  8. Bjornevik K, Zhang Z, O'Reilly ÉJ, Berry JD, Clish CB, Deik A, Jeanfavre S, Kato I, Kelly RS, Kolonel LN, Liang L, Marchand LL, McCullough ML, Paganoni S, Pierce KA, Schwarzschild MA, Shadyab AH, Wactawski-Wende J, Wang DD, Wang Y, Manson JE, Ascherio A. Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. Neurology. 2019 04 30; 92(18):e2089-e2100. PMID: 30926684.
    Citations:    
  9. Bakshi R, Macklin EA, Logan R, Zorlu MM, Xia N, Crotty GF, Zhang E, Chen X, Ascherio A, Schwarzschild MA. Higher urate in LRRK2 mutation carriers resistant to Parkinson disease. Ann Neurol. 2019 Apr; 85(4):593-599. PMID: 30761591.
    Citations:    
  10. Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, Litvan I, Mata IF, Zabetian CP, Brundin P, Fernandez HH, Standaert DG, Kauffman MA, Schwarzschild MA, Sardi SP, Sherer T, Perry G, Leverenz JB. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology. 2019 02 12; 92(7):329-337. PMID: 30745444.
    Citations:    
  11. Ascherio A, Schwarzschild MA. Lifestyle and Parkinson's disease progression. Mov Disord. 2019 01; 34(1):7-8. PMID: 30653733.
    Citations:    Fields:    
  12. Bjornevik K, O'Reilly ÉJ, Berry JD, Clish CB, Jeanfavre S, Kato I, Kolonel LN, Le Marchand L, McCullough ML, Paganoni S, Schwarzschild MA, Talbott EO, Wallace RB, Zhang Z, Manson JE, Ascherio A. Prediagnostic plasma branched-chain amino acids and the risk of amyotrophic lateral sclerosis. Neurology. 2019 04 30; 92(18):e2081-e2088. PMID: 30429276.
    Citations:    Fields:    
  13. Chen X, Umeh CC, Tainsh RE, Feng DD, Maguire M, Zuo F, Rahimian M, Logan R, Wang X, Ascherio A, Macklin EA, Buys ES, Schwarzschild MA. Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease. EBioMedicine. 2018 Nov; 37:259-268. PMID: 30415890.
    Citations:    
  14. Nicholson K, Chan J, Macklin EA, Levine-Weinberg M, Breen C, Bakshi R, Grasso DL, Wills AM, Jahandideh S, Taylor AA, Beaulieu D, Ennist DL, Andronesi O, Ratai EM, Schwarzschild MA, Cudkowicz M, Paganoni S. Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2018 Dec; 5(12):1522-1533. PMID: 30564619.
    Citations:    
  15. Bhattacharyya S, Macklin EA, Schwarzschild MA. Cardiovascular Safety of Febuxostat. N Engl J Med. 2018 10 18; 379(16):1582. PMID: 30338966.
    Citations:    Fields:    Translation:Humans
  16. Palacios N, Hughes KC, Cereda E, Schwarzschild MA, Ascherio A. Appendectomy and risk of Parkinson's disease in two large prospective cohorts of men and women. Mov Disord. 2018 09; 33(9):1492-1496. PMID: 30218460.
    Citations:    Fields:    
  17. Iwaki H, Hughes KC, Gao X, Schwarzschild MA, Ascherio A. The association between restless legs syndrome and premotor symptoms of Parkinson's disease. J Neurol Sci. 2018 11 15; 394:41-44. PMID: 30212740.
    Citations:    Fields:    
  18. Hughes KC, Gao X, Baker JM, Stephen C, Kim IY, Valeri L, Schwarzschild MA, Ascherio A. Non-motor features of Parkinson's disease in a nested case-control study of US men. J Neurol Neurosurg Psychiatry. 2018 12; 89(12):1288-1295. PMID: 30076266.
    Citations:    Fields:    
  19. Bakshi R, Xu Y, Mueller KA, Chen X, Granucci E, Paganoni S, Sadri-Vakili G, Schwarzschild MA. Urate mitigates oxidative stress and motor neuron toxicity of astrocytes derived from ALS-linked SOD1G93A mutant mice. Mol Cell Neurosci. 2018 10; 92:12-16. PMID: 29928993.
    Citations:    Fields:    
  20. Hughes KC, Gao X, O'Reilly EJ, Kim IY, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Genetic variants related to urate and risk of Parkinson's disease. Parkinsonism Relat Disord. 2018 08; 53:4-9. PMID: 29789205.
    Citations:    Fields:    
  21. Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, Hannan MT, Betensky RA, Ascherio A. Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts. Neurology. 2018 05 08; 90(19):e1646-e1653. PMID: 29643081.
    Citations:    Fields:    
  22. Cai W, Feng D, Schwarzschild MA, McLean PJ, Chen X. Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice. EBioMedicine. 2018 Mar; 29:13-22. PMID: 29433982.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  23. Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, McCullough ML, Hannan MT, Betensky RA, Ascherio A. Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk. Mov Disord. 2018 03; 33(3):414-420. PMID: 29318639.
    Citations:    Fields:    
  24. O'Reilly ÉJ, Bjornevik K, Schwarzschild MA, McCullough ML, Kolonel LN, Le Marchand L, Manson JE, Ascherio A. Pre-diagnostic plasma urate and the risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018 05; 19(3-4):194-200. PMID: 29277115.
    Citations:    Fields:    Translation:Humans
  25. Ascherio A, Schwarzschild MA. Dietary antioxidants and Parkinson's disease. Mov Disord. 2017 11; 32(11):1501-1503. PMID: 28976040.
    Citations:    Fields:    Translation:Humans
  26. Palacios N, Fitzgerald KC, Hart JE, Weisskopf M, Schwarzschild MA, Ascherio A, Laden F. Air Pollution and Risk of Parkinson's Disease in a Large Prospective Study of Men. Environ Health Perspect. 2017 08 18; 125(8):087011. PMID: 28886605.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  27. Crotty GF, Ascherio A, Schwarzschild MA. Targeting urate to reduce oxidative stress in Parkinson disease. Exp Neurol. 2017 12; 298(Pt B):210-224. PMID: 28622913.
    Citations: 4     Fields:    Translation:HumansAnimals
  28. Hughes KC, Gao X, Kim IY, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Intake of dairy foods and risk of Parkinson disease. Neurology. 2017 Jul 04; 89(1):46-52. PMID: 28596209.
    Citations: 5     Fields:    Translation:Humans
  29. Quinti L, Dayalan Naidu S, Träger U, Chen X, Kegel-Gleason K, Llères D, Connolly C, Chopra V, Low C, Moniot S, Sapp E, Tousley AR, Vodicka P, Van Kanegan MJ, Kaltenbach LS, Crawford LA, Fuszard M, Higgins M, Miller JRC, Farmer RE, Potluri V, Samajdar S, Meisel L, Zhang N, Snyder A, Stein R, Hersch SM, Ellerby LM, Weerapana E, Schwarzschild MA, Steegborn C, Leavitt BR, Degterev A, Tabrizi SJ, Lo DC, DiFiglia M, Thompson LM, Dinkova-Kostova AT, Kazantsev AG. KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients. Proc Natl Acad Sci U S A. 2017 06 06; 114(23):E4676-E4685. PMID: 28533375.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  30. Chen X, Feng D, Schwarzschild MA, Gao X. Red hair, MC1R variants, and risk for Parkinson's disease - a meta-analysis. Ann Clin Transl Neurol. 2017 03; 4(3):212-216. PMID: 28275654.
    Citations: 1     
  31. Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, Brundin P, Kauffman MA, Erro R, Kieburtz K, Woo D, Macklin EA, Standaert DG, Lang AE. Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. Mov Disord. 2017 03; 32(3):319-324. PMID: 28233927.
    Citations: 7     Fields:    Translation:Humans
  32. Chen X, Chen H, Cai W, Maguire M, Ya B, Zuo F, Logan R, Li H, Robinson K, Vanderburg CR, Yu Y, Wang Y, Fisher DE, Schwarzschild MA. The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival. Ann Neurol. 2017 Mar; 81(3):395-406. PMID: 28019657.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  33. Schwarzschild MA. Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects? J Parkinsons Dis. 2017; 7(1):79-80. PMID: 28035939.
    Citations:    Fields:    
  34. Paganoni S, Schwarzschild MA. Urate as a Marker of Risk and Progression of Neurodegenerative Disease. Neurotherapeutics. 2017 01; 14(1):148-153. PMID: 27995438.
    Citations: 6     Fields:    Translation:HumansAnimals
  35. Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, Ascherio A. Differences in Parkinson's Disease Risk with Caffeine Intake and Postmenopausal Hormone Use. J Parkinsons Dis. 2017; 7(4):677-684. PMID: 28984617.
    Citations:    Fields:    Translation:Humans
  36. Hughes KC, Gao X, Kim IY, Rimm EB, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Intake of antioxidant vitamins and risk of Parkinson's disease. Mov Disord. 2016 12; 31(12):1909-1914. PMID: 27787934.
    Citations: 3     Fields:    Translation:Humans
  37. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol. 2016 Nov; 15(12):1257-1272. PMID: 27751556.
    Citations: 47     Fields:    Translation:Humans
  38. O'Reilly ÉJ, Liu D, Johns DR, Cudkowicz ME, Paganoni S, Schwarzschild MA, Leitner M, Ascherio A. Serum urate at trial entry and ALS progression in EMPOWER. Amyotroph Lateral Scler Frontotemporal Degener. 2017 02; 18(1-2):120-125. PMID: 27677562.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  39. Jackson EK, Boison D, Schwarzschild MA, Kochanek PM. Purines: forgotten mediators in traumatic brain injury. J Neurochem. 2016 Apr; 137(2):142-53. PMID: 26809224.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  40. Xu K, Di Luca DG, Orrú M, Xu Y, Chen JF, Schwarzschild MA. Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors. Neuroscience. 2016 May 13; 322:129-37. PMID: 26905951.
    Citations: 11     Fields:    Translation:AnimalsCells
  41. Bhattacharyya S, Bakshi R, Logan R, Ascherio A, Macklin EA, Schwarzschild MA. Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease. Mov Disord. 2016 Mar; 31(3):417-21. PMID: 26805433.
    Citations: 5     Fields:    Translation:Humans
  42. Gao X, O'Reilly ÉJ, Schwarzschild MA, Ascherio A. Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology. 2016 Feb 09; 86(6):520-6. PMID: 26764029.
    Citations: 22     Fields:    Translation:Humans
  43. Bakshi R, Zhang H, Logan R, Joshi I, Xu Y, Chen X, Schwarzschild MA. Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release. Neurobiol Dis. 2015 Oct; 82:574-579. PMID: 26341543.
    Citations: 13     Fields:    Translation:AnimalsCells
  44. Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, Schwarzschild MA, Hayes MT, Wills AM, Shivraj Sohur U, Mejia NI, Selkoe DJ, Oakes D, Shoulson I, Dong X, Marek K, Zheng B, Ivinson A, Hyman BT, Growdon JH, Sudarsky LR, Schlossmacher MG, Ravina B, Scherzer CR. Association between a-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. Brain. 2015 Sep; 138(Pt 9):2659-71. PMID: 26220939.
    Citations: 16     Fields:    Translation:Humans
  45. Chen X, Wales P, Quinti L, Zuo F, Moniot S, Herisson F, Rauf NA, Wang H, Silverman RB, Ayata C, Maxwell MM, Steegborn C, Schwarzschild MA, Outeiro TF, Kazantsev AG. The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia. PLoS One. 2015; 10(1):e0116919. PMID: 25608039.
    Citations: 23     Fields:    Translation:HumansAnimalsCells
  46. Palacios N, Fitzgerald KC, Hart JE, Weisskopf MG, Schwarzschild MA, Ascherio A, Laden F. Particulate matter and risk of Parkinson disease in a large prospective study of women. Environ Health. 2014 Oct 07; 13:80. PMID: 25294559.
    Citations: 9     Fields:    Translation:HumansPHPublic Health
  47. Simon KC, Eberly S, Gao X, Oakes D, Tanner CM, Shoulson I, Fahn S, Schwarzschild MA, Ascherio A. Mendelian randomization of serum urate and parkinson disease progression. Ann Neurol. 2014 Dec; 76(6):862-8. PMID: 25257975.
    Citations: 20     Fields:    Translation:Humans
  48. Schwarzschild MA, Macklin EA, Ascherio A. Urate and neuroprotection trials. Lancet Neurol. 2014 Aug; 13(8):758. PMID: 25030508.
    Citations: 7     Fields:    Translation:Humans
  49. Palacios N, Fitzgerald K, Roberts AL, Hart JE, Weisskopf MG, Schwarzschild MA, Ascherio A, Laden F. A prospective analysis of airborne metal exposures and risk of Parkinson disease in the nurses' health study cohort. Environ Health Perspect. 2014 Sep; 122(9):933-8. PMID: 24905870.
    Citations: 11     Fields:    Translation:HumansPHPublic Health
  50. Cipriani S, Bakshi R, Schwarzschild MA. Protection by inosine in a cellular model of Parkinson's disease. Neuroscience. 2014 Aug 22; 274:242-9. PMID: 24880154.
    Citations: 6     Fields:    Translation:AnimalsCells
  51. Kachroo A, Schwarzschild MA. Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson's disease. Brain Res. 2014 May 14; 1563:103-9. PMID: 24680743.
    Citations: 3     Fields:    Translation:AnimalsCells
  52. Wong JC, Li Y, Schwarzschild MA, Ascherio A, Gao X. Restless legs syndrome: an early clinical feature of Parkinson disease in men. Sleep. 2014 Feb 01; 37(2):369-72. PMID: 24497665.
    Citations: 15     Fields:    Translation:Humans
  53. Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb; 71(2):141-50. PMID: 24366103.
    Citations: 44     Fields:    Translation:Humans
  54. McFarland NR, Dimant H, Kibuuka L, Ebrahimi-Fakhari D, Desjardins CA, Danzer KM, Danzer M, Fan Z, Schwarzschild MA, Hirst W, McLean PJ. Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not a-synuclein-induced neuronal cell loss. PLoS One. 2014; 9(1):e86048. PMID: 24465863.
    Citations: 11     Fields:    Translation:HumansAnimals
  55. Hung AY, Schwarzschild MA. Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline? Neurotherapeutics. 2014 Jan; 11(1):34-46. PMID: 24310604.
    Citations: 7     Fields:    Translation:HumansAnimals
  56. Ding H, Dhima K, Lockhart KC, Locascio JJ, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Hayes MT, Sohur US, Wills AM, Mollenhauer B, Flaherty AW, Hung AY, Mejia N, Khurana V, Gomperts SN, Selkoe DJ, Schwarzschild MA, Schlossmacher MG, Hyman BT, Sudarsky LR, Growdon JH, Scherzer CR. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology. 2013 Oct 22; 81(17):1531-7. PMID: 24068787.
    Citations: 22     Fields:    Translation:Humans
  57. McFarland NR, Burdett T, Desjardins CA, Frosch MP, Schwarzschild MA. Postmortem brain levels of urate and precursors in Parkinson's disease and related disorders. Neurodegener Dis. 2013; 12(4):189-98. PMID: 23467193.
    Citations: 6     Fields:    Translation:HumansCells
  58. Wills AM, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA. Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord. 2013 Mar; 28(3):380-3. PMID: 23339054.
    Citations: 11     Fields:    Translation:Humans
  59. Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburtz K, Lees AJ, Schwarzschild MA, Tanner CM, Isaacs T, Duffen J, Matthews H, Wyse RK. Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. J Parkinsons Dis. 2013 Jan 01; 3(3):231-9. PMID: 24018336.
    Citations: 5     Fields:    Translation:Humans
  60. Chen X, Burdett TC, Desjardins CA, Logan R, Cipriani S, Xu Y, Schwarzschild MA. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc Natl Acad Sci U S A. 2013 Jan 02; 110(1):300-5. PMID: 23248282.
    Citations: 33     Fields:    Translation:AnimalsCells
  61. Gao X, Simon KC, Schwarzschild MA, Ascherio A. Age, statin use, and the risk for incident Parkinson disease-reply. Arch Neurol. 2012 Oct 1; 69(10):1381. PMID: 23044597.
    Citations:    
  62. Gao X, Simon KC, Schwarzschild MA, Ascherio A. Age, statin use, and the risk for incident Parkinson disease-reply. Arch Neurol. 2012 Oct 01; 69(10):1381. PMID: 23754004.
    Citations:    Fields:    
  63. Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal F, Beck J, Flagg E, Galpern WR, Harman J, Lang AE, Schwarzschild M, Tanner C, Shoulson I. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord. 2012 Sep 15; 27(11):1392-7. PMID: 22976926.
    Citations: 24     Fields:    Translation:Humans
  64. Salamone JD, Collins-Praino LE, Pardo M, Podurgiel SJ, Baqi Y, Müller CE, Schwarzschild MA, Correa M. Conditional neural knockout of the adenosine A(2A) receptor and pharmacological A(2A) antagonism reduce pilocarpine-induced tremulous jaw movements: studies with a mouse model of parkinsonian tremor. Eur Neuropsychopharmacol. 2013 Aug; 23(8):972-7. PMID: 22947264.
    Citations: 6     Fields:    Translation:AnimalsCells
  65. Palacios N, Gao X, McCullough ML, Schwarzschild MA, Shah R, Gapstur S, Ascherio A. Caffeine and risk of Parkinson's disease in a large cohort of men and women. Mov Disord. 2012 Sep 01; 27(10):1276-82. PMID: 22927157.
    Citations: 32     Fields:    Translation:Humans
  66. Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Protection of dopaminergic cells by urate requires its accumulation in astrocytes. J Neurochem. 2012 Oct; 123(1):172-81. PMID: 22671773.
    Citations: 11     Fields:    Translation:AnimalsCells
  67. Chen X, Wu G, Schwarzschild MA. Urate in Parkinson's disease: more than a biomarker? Curr Neurol Neurosci Rep. 2012 Aug; 12(4):367-75. PMID: 22580741.
    Citations: 17     Fields:    Translation:HumansAnimals
  68. Schwarzschild MA. Caffeine in Parkinson disease: better for cruise control than snooze patrol? Neurology. 2012 Aug 14; 79(7):616-8. PMID: 22855870.
    Citations: 4     Fields:    Translation:Humans
  69. Palacios N, Gao X, O'Reilly E, Schwarzschild M, McCullough ML, Mayo T, Gapstur SM, Ascherio AA. Alcohol and risk of Parkinson's disease in a large, prospective cohort of men and women. Mov Disord. 2012 Jul; 27(8):980-7. PMID: 22714720.
    Citations: 14     Fields:    Translation:Humans
  70. Burdett TC, Desjardins CA, Logan R, McFarland NR, Chen X, Schwarzschild MA. Efficient determination of purine metabolites in brain tissue and serum by high-performance liquid chromatography with electrochemical and UV detection. Biomed Chromatogr. 2013 Jan; 27(1):122-9. PMID: 22674671.
    Citations: 5     Fields:    Translation:HumansAnimals
  71. Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease. PLoS One. 2012; 7(5):e37331. PMID: 22606360.
    Citations: 20     Fields:    Translation:AnimalsCells
  72. Gao X, Cassidy A, Schwarzschild MA, Rimm EB, Ascherio A. Habitual intake of dietary flavonoids and risk of Parkinson disease. Neurology. 2012 Apr 10; 78(15):1138-45. PMID: 22491871.
    Citations: 33     Fields:    Translation:HumansAnimals
  73. Gao X, Simon KC, Schwarzschild MA, Ascherio A. Prospective study of statin use and risk of Parkinson disease. Arch Neurol. 2012 Mar; 69(3):380-4. PMID: 22410446.
    Citations: 30     Fields:    Translation:Humans
  74. Matos M, Augusto E, Santos-Rodrigues AD, Schwarzschild MA, Chen JF, Cunha RA, Agostinho P. Adenosine A2A receptors modulate glutamate uptake in cultured astrocytes and gliosomes. Glia. 2012 May; 60(5):702-16. PMID: 22298379.
    Citations: 31     Fields:    Translation:AnimalsCells
  75. Kachroo A, Schwarzschild MA. Adenosine A2A receptor gene disruption protects in an a-synuclein model of Parkinson's disease. Ann Neurol. 2012 Feb; 71(2):278-82. PMID: 22367999.
    Citations: 18     Fields:    Translation:Animals
  76. Palacios N, Gao X, Schwarzschild M, Ascherio A. Declining quality of life in Parkinson disease before and after diagnosis. J Parkinsons Dis. 2012; 2(2):153-60. PMID: 23939439.
    Citations: 1     Fields:    Translation:Humans
  77. Ding H, Sarokhan AK, Roderick SS, Bakshi R, Maher NE, Ashourian P, Kan CG, Chang S, Santarlasci A, Swords KE, Ravina BM, Hayes MT, Sohur US, Wills AM, Flaherty AW, Unni VK, Hung AY, Selkoe DJ, Schwarzschild MA, Schlossmacher MG, Sudarsky LR, Growdon JH, Ivinson AJ, Hyman BT, Scherzer CR. Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study. Mov Disord. 2011 Oct; 26(12):2283-6. PMID: 21953863.
    Citations: 9     Fields:    Translation:Humans
  78. Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, Mailman R, Chen H. Serum cholesterol and the progression of Parkinson's disease: results from DATATOP. PLoS One. 2011; 6(8):e22854. PMID: 21853051.
    Citations: 8     Fields:    Translation:Humans
  79. Palacios N, Gao X, McCullough ML, Jacobs EJ, Patel AV, Mayo T, Schwarzschild MA, Ascherio A. Obesity, diabetes, and risk of Parkinson's disease. Mov Disord. 2011 Oct; 26(12):2253-9. PMID: 21739472.
    Citations: 19     Fields:    Translation:Humans
  80. Gao X, Chen H, Schwarzschild MA, Ascherio A. A prospective study of bowel movement frequency and risk of Parkinson's disease. Am J Epidemiol. 2011 Sep 01; 174(5):546-51. PMID: 21719744.
    Citations: 21     Fields:    Translation:Humans
  81. Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A. Serum urate and probability of dopaminergic deficit in early "Parkinson's disease". Mov Disord. 2011 Aug 15; 26(10):1864-8. PMID: 21538532.
    Citations: 12     Fields:    Translation:Humans
  82. Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology. 2011 Mar 08; 76(10):863-9. PMID: 21368281.
    Citations: 67     Fields:    Translation:Humans
  83. Barkhoudarian MT, Schwarzschild MA. Preclinical jockeying on the translational track of adenosine A2A receptors. Exp Neurol. 2011 Apr; 228(2):160-4. PMID: 21211537.
    Citations: 4     Fields:    Translation:HumansAnimals
  84. Schwarzschild MA. The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology. 2010 Nov 23; 75(21):1943-4; author reply 1944-5. PMID: 21098412.
    Citations: 1     Fields:    Translation:Humans
  85. Gao X, Schwarzschild MA, O'Reilly EJ, Wang H, Ascherio A. Restless legs syndrome and Parkinson's disease in men. Mov Disord. 2010 Nov 15; 25(15):2654-7. PMID: 20737545.
    Citations: 12     Fields:    Translation:Humans
  86. Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomark Med. 2010 Oct; 4(5):701-12. PMID: 20945982.
    Citations: 35     Fields:    Translation:Humans
  87. Black YD, Xiao D, Pellegrino D, Kachroo A, Brownell AL, Schwarzschild MA. Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease. Neurosci Lett. 2010 Dec 17; 486(3):161-5. PMID: 20854878.
    Citations: 6     Fields:    Translation:Animals
  88. Simon KC, Gao X, Chen H, Schwarzschild MA, Ascherio A. Calcium channel blocker use and risk of Parkinson's disease. Mov Disord. 2010 Sep 15; 25(12):1818-22. PMID: 20669249.
    Citations: 14     Fields:    Translation:Humans
  89. Xiao D, Cassin JJ, Healy B, Burdett TC, Chen JF, Fredholm BB, Schwarzschild MA. Deletion of adenosine A1 or A(2A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease. Brain Res. 2011 Jan 07; 1367:310-8. PMID: 20828543.
    Citations: 15     Fields:    Translation:Animals
  90. Gardener H, Gao X, Chen H, Schwarzschild MA, Spiegelman D, Ascherio A. Prenatal and early life factors and risk of Parkinson's disease. Mov Disord. 2010 Aug 15; 25(11):1560-7. PMID: 20740569.
    Citations: 5     Fields:    Translation:Humans
  91. O'Reilly EJ, Gao X, Weisskopf MG, Chen H, Schwarzschild MA, Spiegelman D, Ascherio A. Plasma urate and Parkinson's disease in women. Am J Epidemiol. 2010 Sep 15; 172(6):666-70. PMID: 20682521.
    Citations: 20     Fields:    Translation:Humans
  92. Palacios N, Weisskopf M, Simon K, Gao X, Schwarzschild M, Ascherio A. Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women. Parkinsonism Relat Disord. 2010 Jul; 16(6):370-5. PMID: 20304699.
    Citations: 11     Fields:    Translation:Humans
  93. Kachroo A, Irizarry MC, Schwarzschild MA. Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Exp Neurol. 2010 Jun; 223(2):657-61. PMID: 20188092.
    Citations: 22     Fields:    Translation:AnimalsCells
  94. Schwarzschild MA. Rasagiline in Parkinson's disease. N Engl J Med. 2010 Feb 18; 362(7):658; author reply 658-9. PMID: 20187261.
    Citations: 3     Fields:    Translation:Humans
  95. Youdim MB. Rasagiline in Parkinson's disease. N Engl J Med. 2010 Feb 18; 362(7):657-8; author reply 658-9. PMID: 20164492.
    Citations: 4     Fields:    Translation:HumansAnimals
  96. Xu K, Xu YH, Chen JF, Schwarzschild MA. Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience. 2010 May 05; 167(2):475-81. PMID: 20167258.
    Citations: 21     Fields:    Translation:Animals
  97. Gao X, Schwarzschild MA, O'Reilly EJ, Wang H, Ascherio A. Restless legs syndrome and erectile dysfunction. Sleep. 2010 Jan; 33(1):75-9. PMID: 20120623.
    Citations: 8     Fields:    Translation:Humans
  98. Morelli M, Carta AR, Kachroo A, Schwarzschild MA. Pathophysiological roles for purines: adenosine, caffeine and urate. Prog Brain Res. 2010; 183:183-208. PMID: 20696321.
    Citations: 23     Fields:    Translation:Humans
  99. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009 Dec; 66(12):1460-8. PMID: 19822770.
    Citations: 86     Fields:    Translation:Humans
  100. Quiroz C, Luján R, Uchigashima M, Simoes AP, Lerner TN, Borycz J, Kachroo A, Canas PM, Orru M, Schwarzschild MA, Rosin DL, Kreitzer AC, Cunha RA, Watanabe M, Ferré S. Key modulatory role of presynaptic adenosine A2A receptors in cortical neurotransmission to the striatal direct pathway. ScientificWorldJournal. 2009 Nov 18; 9:1321-44. PMID: 19936569.
    Citations: 32     Fields:    Translation:AnimalsCells
  101. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Family history of melanoma and Parkinson disease risk. Neurology. 2009 Oct 20; 73(16):1286-91. PMID: 19841380.
    Citations: 33     Fields:    Translation:Humans
  102. Carta AR, Kachroo A, Schintu N, Xu K, Schwarzschild MA, Wardas J, Morelli M. Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem. 2009 Dec; 111(6):1478-89. PMID: 19817968.
    Citations: 14     Fields:    Translation:AnimalsCells
  103. Simon KC, Chen H, Gao X, Schwarzschild MA, Ascherio A. Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease. Mov Disord. 2009 Jul 15; 24(9):1359-65. PMID: 19424986.
    Citations: 18     Fields:    Translation:Humans
  104. McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, McLean PJ. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J Neuropathol Exp Neurol. 2009 May; 68(5):515-24. PMID: 19525899.
    Citations: 37     Fields:    Translation:HumansAnimalsCells
  105. Gao X, Schwarzschild MA, Wang H, Ascherio A. Obesity and restless legs syndrome in men and women. Neurology. 2009 Apr 07; 72(14):1255-61. PMID: 19349606.
    Citations: 46     Fields:    Translation:Humans
  106. O'Reilly EJ, Chen H, Gardener H, Gao X, Schwarzschild MA, Ascherio A. Smoking and Parkinson's disease: using parental smoking as a proxy to explore causality. Am J Epidemiol. 2009 Mar 15; 169(6):678-82. PMID: 19131566.
    Citations: 17     Fields:    Translation:Humans
  107. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Genetic determinants of hair color and Parkinson's disease risk. Ann Neurol. 2009 Jan; 65(1):76-82. PMID: 19194882.
    Citations: 32     Fields:    Translation:Humans
  108. Petzer JP, Castagnoli N, Schwarzschild MA, Chen JF, Van der Schyf CJ. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease. Neurotherapeutics. 2009 Jan; 6(1):141-51. PMID: 19110205.
    Citations: 10     Fields:    Translation:HumansAnimals
  109. Yang JN, Björklund O, Lindström-Törnqvist K, Lindgren E, Eriksson TM, Kahlström J, Chen JF, Schwarzschild MA, Tobler I, Fredholm BB. Mice heterozygous for both A1 and A(2A) adenosine receptor genes show similarities to mice given long-term caffeine. J Appl Physiol (1985). 2009 Feb; 106(2):631-9. PMID: 19036889.
    Citations: 15     Fields:    Translation:AnimalsCells
  110. Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, Peterson RC, Ascherio A, Aisen PS. Plasma urate and progression of mild cognitive impairment. Neurodegener Dis. 2009; 6(1-2):23-8. PMID: 19066433.
    Citations: 34     Fields:    Translation:Humans
  111. Bronstein J, Carvey P, Chen H, Cory-Slechta D, DiMonte D, Duda J, English P, Goldman S, Grate S, Hansen J, Hoppin J, Jewell S, Kamel F, Koroshetz W, Langston JW, Logroscino G, Nelson L, Ravina B, Rocca W, Ross GW, Schettler T, Schwarzschild M, Scott B, Seegal R, Singleton A, Steenland K, Tanner CM, Van Den Eeden S, Weisskopf M. Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007. Environ Health Perspect. 2009 Jan; 117(1):117-21. PMID: 19165397.
    Citations: 16     Fields:    Translation:Humans
  112. Tikh EI, Fenton RA, Chen JF, Schwarzschild MA, Dobson JG. Adenosine A1 and A2A receptor regulation of protein phosphatase 2A in the murine heart. J Cell Physiol. 2008 Jul; 216(1):83-90. PMID: 18181173.
    Citations: 8     Fields:    Translation:AnimalsCells
  113. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A, Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, Goetz C, Seibyl J, Forrest M, Ondrasik J. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008 Jun; 65(6):716-23. PMID: 18413464.
    Citations: 92     Fields:    Translation:Humans
  114. Gao X, Chen H, Schwarzschild MA, Logroscino G, Ascherio A. Perceived imbalance and risk of Parkinson's disease. Mov Disord. 2008 Mar 15; 23(4):613-6. PMID: 18181208.
    Citations: 6     Fields:    Translation:Humans
  115. Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, Ascherio A. Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol. 2008 Apr 01; 167(7):831-8. PMID: 18326873.
    Citations: 54     Fields:    Translation:Humans
  116. Wang H, Chen H, Gao X, McGrath M, Deer D, De Vivo I, Schwarzschild MA, Ascherio A. Telomere length and risk of Parkinson's disease. Mov Disord. 2008 Jan 30; 23(2):302-5. PMID: 18044760.
    Citations: 34     Fields:    Translation:HumansCells
  117. Thacker EL, Chen H, Patel AV, McCullough ML, Calle EE, Thun MJ, Schwarzschild MA, Ascherio A. Recreational physical activity and risk of Parkinson's disease. Mov Disord. 2008 Jan; 23(1):69-74. PMID: 17960818.
    Citations: 45     Fields:    Translation:Humans
  118. Schwarzschild MA (guest editor) Zigmond M (editor). "Targeting Adenosine A2A Receptors in Parkinson's Disease and other CNS Disorders". Progress in Neurobiology [journal Special Issue]. 2007; 261-347.
  119. Tebano MT, Martire A, Potenza RL, Grò C, Pepponi R, Armida M, Domenici MR, Schwarzschild MA, Chen JF, Popoli P. Adenosine A(2A) receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus. J Neurochem. 2008 Jan; 104(1):279-86. PMID: 18005343.
    Citations: 23     Fields:    Translation:AnimalsCells
  120. Gao X, Chen H, Fung TT, Logroscino G, Schwarzschild MA, Hu FB, Ascherio A. Prospective study of dietary pattern and risk of Parkinson disease. Am J Clin Nutr. 2007 Nov; 86(5):1486-94. PMID: 17991663.
    Citations: 43     Fields:    Translation:Humans
  121. Schwarzschild MA. Adenosine A2A antagonists as neurotherapeutics: crossing the bridge. Prog Neurobiol. 2007 Dec; 83(5):261-2. PMID: 17997007.
    Citations: 8     Fields:    Translation:HumansAnimals
  122. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol. 2008 Jan 01; 167(1):90-5. PMID: 17890755.
    Citations: 81     Fields:    Translation:Humans
  123. Gao X, Chen H, Schwarzschild MA, Glasser DB, Logroscino G, Rimm EB, Ascherio A. Erectile function and risk of Parkinson's disease. Am J Epidemiol. 2007 Dec 15; 166(12):1446-50. PMID: 17875583.
    Citations: 21     Fields:    Translation:Humans
  124. Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology. 2007 Oct 23; 69(17):1688-95. PMID: 17761552.
    Citations: 55     Fields:    Translation:Humans
  125. Hung AY, Schwarzschild MA. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility? Curr Opin Neurol. 2007 Aug; 20(4):477-83. PMID: 17620885.
    Citations: 16     Fields:    Translation:HumansAnimals
  126. Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog Neurobiol. 2007 Dec; 83(5):293-309. PMID: 17826884.
    Citations: 38     Fields:    Translation:HumansAnimals
  127. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol. 2007 Sep 01; 166(5):561-7. PMID: 17584757.
    Citations: 98     Fields:    Translation:Humans
  128. Thacker EL, O'Reilly EJ, Weisskopf MG, Chen H, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology. 2007 Mar 06; 68(10):764-8. PMID: 17339584.
    Citations: 54     Fields:    Translation:Humans
  129. Chen H, O'Reilly E, McCullough ML, Rodriguez C, Schwarzschild MA, Calle EE, Thun MJ, Ascherio A. Consumption of dairy products and risk of Parkinson's disease. Am J Epidemiol. 2007 May 01; 165(9):998-1006. PMID: 17272289.
    Citations: 31     Fields:    Translation:Humans
  130. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A. 2007 Jan 16; 104(3):955-60. PMID: 17215369.
    Citations: 138     Fields:    Translation:Humans
  131. Xiao D, Bastia E, Xu YH, Benn CL, Cha JH, Peterson TS, Chen JF, Schwarzschild MA. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J Neurosci. 2006 Dec 27; 26(52):13548-55. PMID: 17192438.
    Citations: 29     Fields:    Translation:Animals
  132. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci. 2006 Nov; 29(11):647-54. PMID: 17030429.
    Citations: 106     Fields:    Translation:HumansAnimals
  133. Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novère N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct; 5(10):845-54. PMID: 17016425.
    Citations: 66     Fields:    Translation:Humans
  134. Ascherio A, Chen H, Weisskopf MG, O'Reilly E, McCullough ML, Calle EE, Schwarzschild MA, Thun MJ. Pesticide exposure and risk for Parkinson's disease. Ann Neurol. 2006 Aug; 60(2):197-203. PMID: 16802290.
    Citations: 89     Fields:    Translation:Humans
  135. Chan ES, Fernandez P, Merchant AA, Montesinos MC, Trzaska S, Desai A, Tung CF, Khoa DN, Pillinger MH, Reiss AB, Tomic-Canic M, Chen JF, Schwarzschild MA, Cronstein BN. Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum. 2006 Aug; 54(8):2632-42. PMID: 16871530.
    Citations: 42     Fields:    Translation:HumansAnimalsCells
  136. Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Ascherio A. Survival of Parkinson's disease patients in a large prospective cohort of male health professionals. Mov Disord. 2006 Jul; 21(7):1002-7. PMID: 16602107.
    Citations: 17     Fields:    Translation:Humans
  137. Chan ES, Montesinos MC, Fernandez P, Desai A, Delano DL, Yee H, Reiss AB, Pillinger MH, Chen JF, Schwarzschild MA, Friedman SL, Cronstein BN. Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol. 2006 Aug; 148(8):1144-55. PMID: 16783407.
    Citations: 70     Fields:    Translation:HumansAnimalsCells
  138. Chen H, Schernhammer E, Schwarzschild MA, Ascherio A. A prospective study of night shift work, sleep duration, and risk of Parkinson's disease. Am J Epidemiol. 2006 Apr 15; 163(8):726-30. PMID: 16495472.
    Citations: 17     Fields:    Translation:Humans
  139. Xu K, Xu Y, Brown-Jermyn D, Chen JF, Ascherio A, Dluzen DE, Schwarzschild MA. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci. 2006 Jan 11; 26(2):535-41. PMID: 16407551.
    Citations: 21     Fields:    Translation:AnimalsCells
  140. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol. 2005 Dec; 58(6):963-7. PMID: 16240369.
    Citations: 141     Fields:    Translation:Humans
  141. Kachroo A, Orlando LR, Grandy DK, Chen JF, Young AB, Schwarzschild MA. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J Neurosci. 2005 Nov 09; 25(45):10414-9. PMID: 16280580.
    Citations: 48     Fields:    Translation:Animals
  142. Tebano MT, Martire A, Rebola N, Pepponi R, Domenici MR, Grò MC, Schwarzschild MA, Chen JF, Cunha RA, Popoli P. Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N-methyl-D-aspartate effects. J Neurochem. 2005 Nov; 95(4):1188-200. PMID: 16271052.
    Citations: 29     Fields:    Translation:AnimalsCells
  143. Yu L, Schwarzschild MA, Chen JF. Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice. Neurosci Lett. 2006 Jan 23; 393(1):31-5. PMID: 16236444.
    Citations: 8     Fields:    Translation:Animals
  144. Frédérick R, Ooms F, Castagnoli N, Petzer JP, Feng JF, Schwarzschild MA, Van der Schyf CJ, Wouters J. (E)-8-(3-Chlorostyryl)-1,3,7-trimethylxanthine, a caffeine derivative acting both as antagonist of adenosine A2A receptors and as inhibitor of MAO-B. Acta Crystallogr C. 2005 Sep; 61(Pt 9):o531-2. PMID: 16143772.
    Citations: 1     Fields:    Translation:Cells
  145. Saura J, Angulo E, Ejarque A, Casadó V, Tusell JM, Moratalla R, Chen JF, Schwarzschild MA, Lluis C, Franco R, Serratosa J. Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. J Neurochem. 2005 Nov; 95(4):919-29. PMID: 16092928.
    Citations: 36     Fields:    Translation:AnimalsCells
  146. Yu L, Haverty PM, Mariani J, Wang Y, Shen HY, Schwarzschild MA, Weng Z, Chen JF. Genetic and pharmacological inactivation of adenosine A2A receptor reveals an Egr-2-mediated transcriptional regulatory network in the mouse striatum. Physiol Genomics. 2005 Sep 21; 23(1):89-102. PMID: 16046619.
    Citations: 4     Fields:    Translation:AnimalsCells
  147. Huang ZL, Qu WM, Eguchi N, Chen JF, Schwarzschild MA, Fredholm BB, Urade Y, Hayaishi O. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci. 2005 Jul; 8(7):858-9. PMID: 15965471.
    Citations: 120     Fields:    Translation:Animals
  148. Bastia E, Xu YH, Scibelli AC, Day YJ, Linden J, Chen JF, Schwarzschild MA. A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization. Neuropsychopharmacology. 2005 May; 30(5):891-900. PMID: 15602504.
    Citations: 34     Fields:    Translation:Animals
  149. Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Ascherio A. Physical activity and the risk of Parkinson disease. Neurology. 2005 Feb 22; 64(4):664-9. PMID: 15728289.
    Citations: 69     Fields:    Translation:Humans
  150. Hauser RA, Schwarzschild MA. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Drugs Aging. 2005; 22(6):471-82. PMID: 15974638.
    Citations: 11     Fields:    Translation:Humans
  151. Xu K, Bastia E, Schwarzschild M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol Ther. 2005 Mar; 105(3):267-310. PMID: 15737407.
    Citations: 41     Fields:    Translation:HumansAnimals
  152. Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Logroscino G, Willett WC, Ascherio A. Folate intake and risk of Parkinson's disease. Am J Epidemiol. 2004 Aug 15; 160(4):368-75. PMID: 15286022.
    Citations: 16     Fields:    Translation:Humans
  153. Francis JW, Bastia E, Matthews CC, Parks DA, Schwarzschild MA, Brown RH, Fishman PS. Tetanus toxin fragment C as a vector to enhance delivery of proteins to the CNS. Brain Res. 2004 Jun 11; 1011(1):7-13. PMID: 15140640.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  154. Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Willett WC, Ascherio A. Obesity and the risk of Parkinson's disease. Am J Epidemiol. 2004 Mar 15; 159(6):547-55. PMID: 15003958.
    Citations: 17     Fields:    Translation:Humans
  155. Yu L, Frith MC, Suzuki Y, Peterfreund RA, Gearan T, Sugano S, Schwarzschild MA, Weng Z, Fink JS, Chen JF. Characterization of genomic organization of the adenosine A2A receptor gene by molecular and bioinformatics analyses. Brain Res. 2004 Mar 12; 1000(1-2):156-73. PMID: 15053963.
    Citations: 13     Fields:    Translation:HumansAnimalsCells
  156. Fink JS, Kalda A, Ryu H, Stack EC, Schwarzschild MA, Chen JF, Ferrante RJ. Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage. J Neurochem. 2004 Feb; 88(3):538-44. PMID: 14720203.
    Citations: 11     Fields:    Translation:Animals
  157. Dunah AW, Sirianni AC, Fienberg AA, Bastia E, Schwarzschild MA, Standaert DG. Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Mol Pharmacol. 2004 Jan; 65(1):121-9. PMID: 14722243.
    Citations: 57     Fields:    Translation:AnimalsCells
  158. Schwarzschild MA, Chen J-F & Chase TN. Translating Adenosine A2A Receptor Biology into Novel Therapies for Parkinson's Disease. Neurology [journal supplemental issue]. 2003; S1-111.
  159. Urade Y, Eguchi N, Qu WM, Sakata M, Huang ZL, Chen JF, Schwarzschild MA, Fink JS, Hayaishi O. Sleep regulation in adenosine A2A receptor-deficient mice. Neurology. 2003 Dec 09; 61(11 Suppl 6):S94-6. PMID: 14663019.
    Citations: 29     Fields:    Translation:Animals
  160. Chen JF, Fredduzzi S, Bastia E, Yu L, Moratalla R, Ongini E, Schwarzschild MA. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease. Neurology. 2003 Dec 09; 61(11 Suppl 6):S74-81. PMID: 14663016.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  161. Schwarzschild MA, Xu K, Oztas E, Petzer JP, Castagnoli K, Castagnoli N, Chen JF. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology. 2003 Dec 09; 61(11 Suppl 6):S55-61. PMID: 14663012.
    Citations: 22     Fields:    Translation:AnimalsCells
  162. Castagnoli N, Petzer JP, Steyn S, Castagnoli K, Chen JF, Schwarzschild MA, Van der Schyf CJ. Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists. Neurology. 2003 Dec 09; 61(11 Suppl 6):S62-8. PMID: 14663013.
    Citations: 8     Fields:    Translation:AnimalsCells
  163. Bibbiani F, Oh JD, Petzer JP, Castagnoli N, Chen JF, Schwarzschild MA, Chase TN. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol. 2003 Nov; 184(1):285-94. PMID: 14637099.
    Citations: 37     Fields:    Translation:AnimalsCells
  164. Day YJ, Huang L, McDuffie MJ, Rosin DL, Ye H, Chen JF, Schwarzschild MA, Fink JS, Linden J, Okusa MD. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest. 2003 Sep; 112(6):883-91. PMID: 12975473.
    Citations: 98     Fields:    Translation:AnimalsCells
  165. Chen H, Zhang SM, Hernán MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol. 2003 Aug; 60(8):1059-64. PMID: 12925360.
    Citations: 129     Fields:    Translation:Humans
  166. Hernán MA, Chen H, Schwarzschild MA, Ascherio A. Alcohol consumption and the incidence of Parkinson's disease. Ann Neurol. 2003 Aug; 54(2):170-5. PMID: 12891669.
    Citations: 21     Fields:    Translation:Humans
  167. Weisskopf MG, Chen H, Schwarzschild MA, Kawachi I, Ascherio A. Prospective study of phobic anxiety and risk of Parkinson's disease. Mov Disord. 2003 Jun; 18(6):646-51. PMID: 12784267.
    Citations: 35     Fields:    Translation:Humans
  168. Chen JF, Moratalla R, Yu L, Martín AB, Xu K, Bastia E, Hackett E, Alberti I, Schwarzschild MA. Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization. Neuropsychopharmacology. 2003 Jun; 28(6):1086-95. PMID: 12700712.
    Citations: 18     Fields:    Translation:Animals
  169. Petzer JP, Steyn S, Castagnoli KP, Chen JF, Schwarzschild MA, Van der Schyf CJ, Castagnoli N. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists. Bioorg Med Chem. 2003 Apr 03; 11(7):1299-310. PMID: 12628657.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  170. Sharma N & Schwarzschild MA. . Movement disorders during pregnancy. JH Noseworthy, editor. Neurologic Therapeutics: Principles and Practice. 2003; 1((Part 2)):1556 – 1558.
  171. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology. 2003 Mar 11; 60(5):790-5. PMID: 12629235.
    Citations: 45     Fields:    Translation:HumansPHPublic Health
  172. Gomez-Isla T, Irizarry MC, Mariash A, Cheung B, Soto O, Schrump S, Sondel J, Kotilinek L, Day J, Schwarzschild MA, Cha JH, Newell K, Miller DW, Uéda K, Young AB, Hyman BT, Ashe KH. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol Aging. 2003 Mar-Apr; 24(2):245-58. PMID: 12498958.
    Citations: 44     Fields:    Translation:HumansAnimals
  173. Bastia E, Schwarzschild MA. DARPP chocolate: a caffeinated morsel of striatal signaling. Sci STKE. 2003 Jan 14; 2003(165):PE2. PMID: 12527819.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  174. Chen J-F & Schwarzschild MA. Gene Knockout Approach to Adenosine A2A receptors in Parkinson’s disease. Drug Development Research. 2003; 58:354-367.
  175. Schwarzsdchild MA, Chen J-F, Chase TN. A2A antagonists for PD - A prime example of translational neuroscience. Neurology. 2003; 61(11 Suppl 6):S3-4.
  176. Chen JF, Steyn S, Staal R, Petzer JP, Xu K, Van Der Schyf CJ, Castagnoli K, Sonsalla PK, Castagnoli N, Schwarzschild MA. 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism. J Biol Chem. 2002 Sep 27; 277(39):36040-4. PMID: 12130655.
    Citations: 17     Fields:    Translation:AnimalsCells
  177. Leibovich SJ, Chen JF, Pinhal-Enfield G, Belem PC, Elson G, Rosania A, Ramanathan M, Montesinos C, Jacobson M, Schwarzschild MA, Fink JS, Cronstein B. Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. Am J Pathol. 2002 Jun; 160(6):2231-44. PMID: 12057925.
    Citations: 60     Fields:    Translation:AnimalsCells
  178. Montesinos MC, Desai A, Chen JF, Yee H, Schwarzschild MA, Fink JS, Cronstein BN. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. Am J Pathol. 2002 Jun; 160(6):2009-18. PMID: 12057906.
    Citations: 58     Fields:    Translation:Animals